Phibro Animal Health Corporation (PAHC)

Currency in USD
53.07
+3.07(+6.14%)
Closed·
54.79+1.72(+3.24%)
·
Unusual trading volume
Trading near 52-week High
PAHC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
50.2656.30
52 wk Range
16.1656.30
Key Statistics
Prev. Close
50
Open
50.75
Day's Range
50.26-56.3
52 wk Range
16.16-56.3
Volume
646.77K
Average Vol. (3m)
281.65K
1-Year Change
124.0186%
Book Value / Share
8.2
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PAHC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
48.50
Downside
-8.61%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Phibro Animal Health Corporation Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal’s health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock’s diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.

Employees
2475

Phibro Animal Health Corporation Earnings Call Summary for Q2/2026

  • Phibro Animal Health reported Q2 2026 EPS of $0.87, exceeding forecasts by 27.94%, with revenue of $373.9 million, 5.25% above expectations, driving stock up 16.82% to $43.23.
  • Consolidated net sales grew 21% YoY, with the animal health segment up 26%. Adjusted EBITDA increased 41% to $19.9 million, while adjusted net income rose 60%.
  • CEO Jack Bendheim confirmed the company's strategy is working, citing strong growth in animal health sales and EBITDA as evidence of successful execution.
  • Phibro raised FY2026 guidance, projecting net sales of $1.45-1.5 billion (12-16% growth) and adjusted EBITDA of $245-255 million (33-39% growth).
  • Full benefits from the Phibro Forward initiative are expected by FY2027, with the legacy MFA business projected to grow in low to mid-single digits.
Last Updated: 02/05/2026, 09:47 AM
Read Full Transcript
Phibro investor slides for Q2/2026
Phibro Q2 2026 presentation
Last Update: Feb 05, 2026
See full investor slides

Compare PAHC to Peers and Sector

Metrics to compare
PAHC
Peers
Sector
Relationship
P/E Ratio
23.4x4.3x−0.5x
PEG Ratio
0.06−0.070.00
Price / Book
6.5x2.4x2.6x
Price / LTM Sales
1.5x2.6x3.3x
Upside (Analyst Target)
−11.4%14.0%45.7%
Fair Value Upside
Unlock14.3%6.5%Unlock

Analyst Ratings

1 Buy
2 Hold
1 Sell
Ratings:
4 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 48.50
(-8.61% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Morgan Stanley
Hold49.00-7.67%45.00MaintainFeb 05, 2026
BofA Securities
Sell32.00-39.70%27.00MaintainNov 06, 2025
BNP Paribas Exane
Hold37.00-30.28%24.00MaintainSep 04, 2025
Morgan Stanley
Hold34.00-35.93%26.00MaintainAug 29, 2025
JPMorgan
Buy35.00-34.05%25.00UpgradeJul 07, 2025

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.27%
Dividend Yield
0.90%
Industry Median 2.38%
Annualized Payout
0.48
Paid quarterly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Feb 04, 2026
EPS / Forecast
0.87 / 0.68
Revenue / Forecast
373.90M / 355.24M
EPS Revisions
Last 90 days

PAHC Income Statement

People Also Watch

418.69
SITM
+2.05%
12.240
AMPX
+15.69%
8.270
TE
+13.76%
597.95
SNDK
+3.77%
1,230.26
FIX
+7.17%

FAQ

What Is the Phibro (PAHC) Stock Price Today?

The Phibro stock price today is 53.07

What Stock Exchange Does Phibro Trade On?

Phibro is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Phibro?

The stock symbol for Phibro is "PAHC."

Does Phibro Pay Dividends? What’s The Current Dividend Yield?

The Phibro dividend yield is 0.9%.

What Is the Phibro Market Cap?

As of today, Phibro market cap is 2.15B.

What Is Phibro's Earnings Per Share (TTM)?

The Phibro EPS (TTM) is 2.27.

When Is the Next Phibro Earnings Date?

Phibro will release its next earnings report on May 13, 2026.

From a Technical Analysis Perspective, Is PAHC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Phibro Stock Split?

Phibro has split 0 times.

How Many Employees Does Phibro Have?

Phibro has 2475 employees.

What is the current trading status of Phibro (PAHC)?

As of Feb 07, 2026, Phibro (PAHC) is trading at a price of 53.07, with a previous close of 50.00. The stock has fluctuated within a day range of 50.26 to 56.30, while its 52-week range spans from 16.16 to 56.30.

What Is Phibro (PAHC) Price Target According to Analysts?

The average 12-month price target for Phibro is USD48.50, with a high estimate of USD58 and a low estimate of USD38. 1 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an -8.61% Downside potential.

What Is the PAHC Premarket Price?

PAHC's last pre-market stock price is 49.75. The pre-market share volume is 2,750.00, and the stock has decreased by -0.25, or -0.50%.

What Is the PAHC After Hours Price?

PAHC's last after hours stock price is 54.79, the stock has decreased by 1.72, or 3.24%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.